Pluristem Shares Commence Trading on Frankfurt Stock Exchange.NEW YORK -- Pluristem Life Systems, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :PLRS PLRS Position Location Reporting System PLRS Passive Laser Restraint System (Knight Rider/KITT) ), a bio-therapeutic Company dedicated to the commercialization of products for a variety of medical disorders, announced today that its shares have begun trading on Europe's Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. , under the symbol PJT PJT Partners for Just Trade (St. Louis, MO) PJT Practical-Job-Training PJT Pandrol Jackson Technology (railway contractor) PJT Post-Jungian Theory PJT Project File . The International Security Identification Number (ISIN/CUSIP) is US72940P1066 and German Security Code is 813519. Pluristem CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chairman, Mr. Zami Aberman commented, "This new listing on the Frankfurt Stock Exchange gives our Company more market exposure and provides our stock higher liquidity in two major equity markets. We also believe it will enhance cooperation with European scientific companies and institutions in the development of our product portfolio." The Frankfurt listing allows European investors and shareholders to trade Pluristem's shares in their time zone and currency. Located in Frankfurt, Germany, the Frankfurt Stock Exchange is a leading international stock exchange. One of the largest and most efficient exchanges in the world, the Frankfurt Stock Exchange executes over 90 percent of the transactions in the German market and represents a substantial share of the European market. For more information, please visit www.deutsche-boerse.com. About Pluristem Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy stem cell therapy Cell therapy Molecular medicine A technology in which a person's own cells–eg, neuronal stem cells are triggered to revert to their primitive embryonic form, then redifferentiate into mature cells of various organs products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation Bone Marrow Transplantation Definition The bone marrow—the sponge-like tissue found in the center of certain bones—contains stem cells that are the precursors of white blood cells, red blood cells, and platelets. (BMT BMT bone marrow transplantation. BMT, n.pr See bone marrow transplant. BMT Bone marrow transplant, see there ) by improving the engraftment engraftment /en·graft·ment/ (en-graft´ment) incorporation of grafted tissue into the body of the host. Engraftment The process of transplanted stem cells reproducing new cells. of hematopoietic stem cells (HSCs) contained in umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. (CB). Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor bioreactor a container in which living organisms carry out a biological reaction. that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel. www.pluristem.com Safe Harbor Statement This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that this new listing gives our Company more market exposure and provides our stock higher liquidity in two major equity markets; that it will enhance cooperation with European scientific companies and institutions in the development of our product portfolio. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion